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Abstract
Introduction: A multitude of mechanisms have been implicated in the pathophysiology of epilepsy. Objective: To assess mean daily
plasma concentrations of ACTH, cortisol, DHEAS, leu-enkephalin, and beta-endorphin in epileptic patients with complex partial seizures
evolving to tonic-clonic in relation to frequency of seizure occurrence (groups with seizure occurrences — several per week and several
per year) and duration of the disease (groups less than and more than 10 years). We decided to analyse mean daily values of beta-endorphin
and leu-enkephalin because of significant differences in concentrations of these substances in blood during the day.
Material and methods: The study was performed on 17 patients (14 males + 3 females; mean age 31.8 yrs) treated with carbamazepine
(300–1800 mg/day). The control group consisted of six age-matched healthy volunteers. Blood was collected at 8 a.m., 2 p.m., 8 p.m., and
2 a.m. Intergroup analysis was performed with the use of ANOVA Kruskal-Wallis test.
Results: Mean daily concentrations of ACTH and cortisol in the blood of the patients with epilepsy were higher in comparison with those
of the healthy volunteers, independently of the frequency of seizures and duration of the disease. Mean daily concentrations of beta-
-endorphin in the blood of the patients with epilepsy were higher in the groups of patients with more severe clinical course of disease
(with more frequently occurring epilepsy seizures and longer duration of the disease) in comparison with healthy subjects. Mean daily
concentrations of leu-enkephalin in the blood of the patients with epilepsy were higher in the group of patients with short duration of the
disease in comparison with the group with long duration of the disease.
Conclusions:
1. Pituitary-adrenal axis hyperactivity is observed in patients with clinically active epilepsy, independently of the frequency of seizures
and duration of the disease.
2. Changes in endogenous opioid system activity are related to the clinical activity of epilepsy — beta-endorphin concentrations are
connected with frequency of seizures and duration of the disease and leu-enkephalin concentrations with duration of the disease.
3. Endogenous opioid peptides might take part in the neurochemical mechanism of human epilepsy.
(Pol J Endocrinol 2010; 61 (1): 103–110)
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Streszczenie
Wstęp: W patofizjologii padaczki uczestniczy nieokreślona ilość mechanizmów. Celem pracy była ocena średniodobowych osoczowych
stężeń ACTH, kortyzolu, DHEAS, leu-enkefaliny and b-endorfiny u chorych na padaczkę z napadami częściowymi, złożonymi i wtórnie
uogólnionymi, toniczno-klonicznymi w zależności od częstości napadów (grupy z częstością napadów — kilka na tydzień i kilka na rok)
i od czasu trwania choroby (grupy < i > 10 lat). Autorzy zdecydowali się na analizę średniodobowych wartości b-endorfiny i leu-enkefa-
liny z powodu wyraźnych różnic w ich stężeniu we krwi w ciągu doby.
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Materiał i metody: Badanie przeprowadzono u 17 chorych (14 mężczyzn i 3 kobiety; średni wiek 31,8 lat) leczonych karbamazepiną
(300–1800 mg/dzień). Grupa kontrolna składała się z 6 zdrowych ochotników w porównywalnym wieku. Krew pobierano o godzinie 8, 14,
20, 2. W analizie międzygrupowej wykorzystano test ANOVA Kruskala-Wallisa.
Wyniki: Średniodobowe stężenia ACTH i kortyzolu we krwi chorych na padaczkę były wyższe w porównaniu ze zdrowymi niezależnie
od częstości napadów i czasu trwania choroby. Średniodobowe stężenia b-endorfiny we krwi chorych na padaczkę były wyższe w gru-
pach pacjentów z ciężkim przebiegiem klinicznym choroby (z wysoką częstością napadów i długim czasem trwania choroby) w porówna-
niu ze zdrowymi. Średniodobowe stężenia leu-enkefaliny we krwi chorych na padaczkę były wyższe w grupie pacjentów z krótkim
czasem trwania choroby w porównaniu z grupą z długim czasem trwania choroby.
Wnioski:
1. U chorych na padaczkę, niezależnie od częstości napadów i czasu trwania choroby, dochodzi do wzmożonej aktywności osi przysadko-
wo-nadnerczowej.
2. Zmiany w aktywności endogennego układu opioidowego są związane z kliniczną aktywnością padaczki — stężenia b-endorfiny pozo-
stają w związku z częstością napadów i czasem trwania choroby, a stężenia leu-enkefaliny z czasem trwania choroby.
3. Endogenne peptydy opioidowe mogą uczestniczyć w neurochemicznym mechanizmie padaczki u ludzi.
(Endokrynol Pol 2010; 61 (1): 103–110)
Słowa kluczowe: padaczka, ACTH, endorfina, enkefalina, kortyzol, DHEAS, endogenne peptydy opioidowe, endogenne opioidy
Introduction
Neuropsychiatric disorders are one of the main chal-
lenges in human medicine, with epilepsy being one of
the most common serious disorders of the brain. Incre-
asing evidence suggests neuropeptides, particularly opio-
ids, play an important role in epilepsy [1, 2]. Actual know-
ledge in this area is still fragmentary. In the presented
experiment the authors try to define the link between
the proopiomelanocortin (POMC) derived peptides
(ACTH, enkephalin, and endorphin) and epilepsy (type,
pharmacotherapy, and duration of the disease).
A multitude of mechanisms has been implicated in
the pathophysiology of epilepsy. Since the seizure phe-
nomenon is often associated with massive electrical di-
scharges in the brain, most if not all of the neurohumo-
ral transmitters may be considered to have a role in
either pre- or post-seizure events. The localization of
endogenous opioids in the brain suggests that they are
likely to be transmitter candidates for epilepsy [1–7].
Immunohistochemical and immunoassay studies indi-
cate the presence of various types of opioid peptides in
the limbic system, above all in the hippocampus, in
which the presence of prodynorphin and proenkepha-
lin derived peptides is confirmed. Changes in enkepha-
lins and b-endorphin activity in the brain and cerebro-
spinal fluid in epileptic men were among the other
things described [1, 3–6]. In view of the presence of pep-
tic transporting system-1 probably playing a role in en-
dogenous opioid transport through the blood-brain
barrier [8], there is a possibility of concentration asses-
sment of these opioids in plasma. In the transport sys-
tem are saturable and non-saturable mechanisms, and
the system can be influenced by several factors such as
aging, drugs, or stress.
There are some reports indicating possible pro-, but
most frequently anticonvulsant effects of natural opio-
id peptides. Endogenous opioid peptides, through in-
crease of the seizure threshold, may take part in spon-
taneous arrest of seizures and, parallel to that, in the
development of the postictal refractory period, in which,
among other things, its cataleptic action is revealed [1,
2, 4–7, 9–13]. There are also reports indicating the anti-
convulsant effect of ACTH through correction of faulty
enzymatic processes in brain, changes in the intracellu-
lar-extracellular electrolyte ratios, reduction in brain
water, stimulation of the adrenal gland to produce glu-
cocorticoids and corticotrophin-releasing hormone sup-
pression, and data indicating that a fragment of the
ACTH molecule acts as a direct neurotransmitter or does
so through an indirect effect on the GABAA receptor [4,
14–16]. The therapeutic effect of ACTH in humans [16]
may have been caused by potentiation of nerve growth
factor action [17], taking into consideration the fact that
glucocorticoids increase nerve growth factor expression
in the rat brain [18].
The aim of the study was the assessment of plasma
concentrations of ACTH, cortisol, dehydroepiandroste-
rone sulphate (DHEAS), b-endorphin, and leucine en-
kephalin (leu-enkephalin) in patients with complex
partial seizures evolving to tonic-clonic in dependence
relation to frequency of seizure occurrence (groups with
seizure occurrences — several per week and several per
year) and duration of the disease (groups with less than
or more than 10 years). We decided to analyse mean
daily values of b-endorphin and leu-enkephalin becau-
se of significant differences in the concentrations of the-
se substances in blood during the day.
Material and methods
The study was performed on 17 patients (14 males + 3
females; mean age 31.8 ± 10.8) with complex partial se-
izures evolving to tonic-clonic seizures. The epileptic
patients were divided according to frequency of seizu-
re occurrence: group A — several seizures per week,
group B — several seizures per year. The epileptic pa-
tients were also divided according to duration of the
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disease: group C — duration less than 10 years, group
D — duration more than 10 years. All patients were tre-
ated with carbamazepine (300–1800 mg/day). No pa-
tients with diagnosed hypothalamic, hypophyseal, or
adrenocortical abnormalities were included in the stu-
dy. The control group consisted of six age-matched he-
althy volunteers. The investigation was performed with
the approval of the Local Ethics Committee, and all
patients gave their written informed consent to partici-
pate in the study.
In all patients’ and healthy subjects’ blood was col-
lected at 8 a.m., 2 p.m., 8 p.m., and 2 a.m. for the asses-
sment of twenty-four-hour ACTH, cortisol, DHEAS,
b-endorphin, and leu-enkephalin plasma concentra-
tions. The plasma was frozen at –75°C until it was as-
sayed. Concentrations of the studied compounds in
plasma were assessed with the use of RIA method and
commercially available kits: Cis-Bio International, Fran-
cja (ACTH); Orion Diagnostica, Finland (cortisol); DPC,
USA (DHEAS); Phoenix Pharmaceuticals Inc., USA
(b-endorphin, leu-enkephalin). For plasma leu-enke-
phalin concentration assessment, the studied samples
were subjected to previous extraction with the use of
ODS-silica columns (INCSTAR, USA). The sensitivity
of the method amounted to: ACTH — 1 pg/ml; cortisol
— 0.18 mg/dl; DHEAS — 1.1 mg/dl; b-endorphin
— 0.5 pg/ml; leu-enkephalin — 0.5 pg/ml.
The obtained results were subjected to statistical
analysis. Intergroup analysis was performed with the
use of ANOVA Kruskal-Wallis test. The level of statisti-
cal significance amounted to p < 0.05.
Results
In all of the analysed groups of patients with epilepsy
— with low and high frequency of seizures and short
and long duration of the disease — mean daily ACTH
and cortisol concentrations in blood were significantly
higher in comparison with the control group (Tables I–IV).
No significant difference in daily secretions of ACTH
and cortisol between the groups of patients with low
and high frequency of seizures (Tables I, III) and be-
tween the groups of patients with short and long dura-
tion of the disease (Tables II, IV) was shown.
Table I. Mean daily concentrations of ACTH in the blood of
patients with epilepsy in relation to frequency of seizures
occurrence (groups with seizure occurrence — several per week
and several per year) and in the control group
Tabela I. Średnie dobowe stężenie ACTH we krwi chorych
na padaczkę w grupach wydzielonych w zależności od
częstości napadów (kilka napadów na tydzień lub kilka
napadów na rok) i w grupie kontrolnej
ACTH           Group
[pg/ml] Several Seizures/
Control  seizures/year /week
Mean 14.19 25.30 20.36
SD 1.66 9.35 5.72
SEM 0.68 2.96 2.16
N 6 10 7
Table II. Mean daily concentrations of ACTH in the blood of
patients with epilepsy in relation to duration of the disease
(groups less than and more than 10 years) and in the control
group
Tabela II. Średnie dobowe stężenie ACTH we krwi chorych
na padaczkę w grupach wydzielonych w zależności od czasu
trwania choroby (mniej niż 10 lat lub ponad 10 lat) i w grupie
kontrolnej
ACTH           Group
[pg/ml] Duration less Duration more
 Control than 10 years than 10 years
Mean 14.19 20.35 23.93
SD 1.66 3.29 9.79
SEM 0.68 1.24 2.83
N 6 7 10
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Mean daily DHEAS concentrations in the blood of
patients with low and high frequency of seizures and
long duration of the disease did not differ from those
in the control group (Tables V, VI). Only in the group
of patients with short duration of the disease were they
significantly lower in comparison with the control group.
The mean daily concentration of b-endorphin in the
blood of patients with more frequently occurring epi-
lepsy seizures was significantly higher in comparison
with the control group. However, no significant diffe-
rence in daily secretion of b-endorphin between the
group of patients with low frequency of seizures and
the control group and between the groups of patients
with low and high frequencies of seizures was obse-
rved (Table VII). In the group of patients with long du-
ration of the disease a significant increase in b-endor-
phin daily secretion was noted in comparison to pa-
tients with short duration of the disease and the con-
trol group. Daily secretion of b-endorphin in the group
of patients with short duration of the disease did not
differ from the control group (Table VIII).
Table III. Mean daily concentrations of cortisol in the blood of
patients with epilepsy in relation to frequency of seizure
occurrence (groups with seizure occurrence — several per week
and several per year) and in the control group
Tabela III. Średnie dobowe stężenie kortyzolu we krwi
chorych na padaczkę w grupach wydzielonych w zależności
od częstości napadów (kilka napadów na tydzień lub kilka
napadów na rok) i w grupie kontrolnej
Cortisol            Group
[mg/dl] Several Seizures/
Control seizures/year week
Mean 10.09 13.65 13.44
SD 0.96 2.37 3.61
SEM 0.39 0.75 1.36
N 6 10 7
Table IV. Mean daily concentrations of cortisol in the blood
of patients with epilepsy in relation to duration of the disease
(groups less than and more than 10 years) and in the control
group
Tabela IV. Średnie dobowe stężenie kortyzolu we krwi
chorych na padaczkę w grupach wydzielonych w zależności
od czasu trwania choroby (mniej niż 10 lat lub ponad 10 lat)
i w grupie kontrolnej
Cortisol           Group 
[mg/dl] Duration less Duration more
Control than 10 years  than 10 years
Mean 10.09 13.09 13.64
SD 0.96 2.32 2.96
SEM 0.39 0.88 0.86
N 6 7 10
Mean daily concentration of leu-enkephalin in the
blood of patients with epilepsy was significantly higher
in the group of patients with short duration of the dise-
ase in comparison with the group with long duration
of the disease. In all the analysed groups of patients with
epilepsy — with low and high frequency of seizures
and short and long duration of the disease — daily se-
cretion of leu-enkephalin did not differ from that in the
control group (Tables IX, X).
Discussion
We noticed that in patients with clinically active epi-
lepsy, pituitary-adrenal axis hyperactivity was observed
— mean daily concentrations of ACTH and cortisol in
the blood of patients with epilepsy were significantly
higher in comparison to healthy subjects independen-
tly of frequency of seizures and duration of the disease.
We also noticed that the abnormalities in endogenous
opioid system activity were related to the clinical acti-
vity of epilepsy — mean daily concentrations of b-en-
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dorphin in the blood of patients with epilepsy were si-
gnificantly higher in the groups of patients with more
frequently occurring epilepsy seizures and long dura-
tion of the disease, and mean daily concentrations of
leu-enkephalin in blood were significantly higher in the
group of patients with short duration of the disease.
Except for some kinds of epilepsy (for example in-
fantile spasms), the role of the pituitary-adrenal axis in
the initial pathogenesis of epilepsy [16, 19] is rather in-
conspicuous. Seizures may induce hormonal changes
through nervous pathways influencing the hypothala-
mic-pituitary function [16, 20]. Therefore, it seems that
the hormonal disturbances observed by us are secon-
dary to the basic disease (epilepsy). Physiological stress
produces a number of biochemical changes in the body,
including increased ACTH, cortisol, b-endorphin, and
enkephalin concentrations in blood. It is therefore logi-
cal that both cortisol and b-endorphin levels in blood
have been shown to rise after convulsive seizure in man
[21]. Cortisol levels in blood were elevated in patients
with status epilepticus who continued to have a poor
outcome within the first week following seizures. In
patients with status epilepticus, cerebrospinal fluid
b-endorphin levels were also increased, but there was
no correlation between the increase and prognosis [22].
While the significant elevation of cortisol levels asso-
ciated with status epilepticus may be a reflection of the
severe stress situation, the elevated cortisol level itself
may be detrimental — neurons have corticosteroid re-
ceptors and corticosteroids are associated with neuro-
nal damage and have a direct effect on neuronal activi-
ty, including their effect on catecholamine turnover and
protein and energy metabolism [22, 23]. It seems that
hypercortisolaemia occurring in status epilepticus with
bad prognosis described by Calabrese [22] as well as in
the group of epileptic patients with severe clinical co-
urse of the disease analysed by us may contribute to
the pathophysiological state of the conditions. Increased
cortisol values in the blood of patients with epilepsy
were documented in the following reports [20, 21, 24].
It was also shown that increased secretion of cortisol
was a result of increased ACTH secretion [21]. In the
Table V. Mean daily concentrations of DHEAS in the blood of
patients with epilepsy in relation to frequency of seizure
occurrence (groups with seizure occurrence — several per week
and several per year) and in the control group
Tabela V. Średnie dobowe stężenie DHEAS we krwi chorych
na padaczkę w grupach wydzielonych w zależności od
częstości napadów (kilka napadów na tydzień lub kilka
napadów na rok) i w grupie kontrolnej
DHEAS        Group
[mg/dl] Several Seizures/
Control seizures/year /week
Mean 327.55 240.36 218.98
SD 39.81 185.78 183.34
SEM 16.25 58.75 69.30
N 6 10 7
Table VI. Mean daily concentrations of DHEAS in the blood
of patients with epilepsy in relation to duration of the disease
(groups less than and more than 10 years) and in the control
group
Tabela VI. Średnie dobowe stężenie DHEAS we krwi chorych
na padaczkę w grupach wydzielonych w zależności od czasu
trwania choroby (mniej niż 10 lat lub ponad 10 lat) i w grupie
kontrolnej
DHEAS        Group
[mg/dl] Duration less Duration more
Control than 10 years than 10 years
Mean 327.55 161.84 256.92
SD 39.81 171.41 178.92
SEM 16.25 64.79 51.65
N 6 7 10
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study performed by us, we showed that in patients with
epilepsy, disturbances of circadian rhythm of ACTH
concentrations were present. It is known that ACTH
has an anticonvulsive action [15–17, 25]. However, we
do not know if the excessive ACTH secretion observed
in the patients studied by us takes part in the calming
of seizures, or if it is only an effect of chronic stress re-
sponse without such an action. ACTH shows antico-
nvulsive action also in the absence of adrenal tissue [14].
Immunocytochemical studies have shown large concen-
trations of ACTH-binding receptor in the hippocampus
[26]. In Gallagher’s studies [27, 28], patients with tem-
poral epilepsy had increased ACTH concentrations in
blood independently of frequency of seizures and their
treatment. ACTH is an agent with demonstrated effica-
cy in the control of infantile spasms [14–16]. In West
syndrome, pulsatile corticoid therapy was an effective
alternative treatment to ACTH whereas in Lennox-Ga-
staut syndrome general steroids did not lead to a signi-
ficant seizure reduction. In electrical status epilepticus
during slow-wave sleep, treatment with pulsatile corti-
coid therapy seems to be effective [16]. The evaluation
of the endocrine setup in epilepsy is difficult because of
the coexistence of pharmacological interferences with
hormonal function. A decrease in mean amounts of
ACTH in blood was shown in patients with epilepsy
treated with valproic acid [29], of cortisol in patients
receiving phenytoin [30], and a slight increase of ACTH
concentrations in the blood of patients using amizepin
[29]. In Isojarvi’s [31] study, cortisol concentrations in
the blood of epileptic patients were not affected by the-
rapy with carbamazepine. Conversely, DHEAS concen-
trations, which were decreased after two months of car-
bamazepine treatment, remained reduced in patients
with long-term carbamazepine therapy, which is proba-
bly a result of accelerating DHEAS metabolism in the li-
ver by enzyme induction. In another study, men with
epilepsy had significantly lower DHEAS in blood [32, 33].
In our study we observed that an increase in the
concentration of ”big” endogenous opioids in blood
(b-endorphin) was noticed in patients with severe (that
is advanced in time or also in intensity) epilepsy and
liberation of ”small” endogenous opioid (leu-enkepha-
lin) to blood was connected with the primary period of
the disease. The pituitary gland and adrenal glands, the
brain, and the digestive tract are, above all, the places
Table VII. Mean daily concentrations of b-endorphin in the
blood of patients with epilepsy in relation to frequency of
seizure occurrence (groups with seizure occurrence — several
per week and several per year) and in the control group
Tabela VII. Średnie dobowe stężenie b-endorfiny we krwi
chorych na padaczkę w grupach wydzielonych w zależności
od częstości napadów (kilka napadów na tydzień lub kilka
napadów na rok) i w grupie kontrolnej
b-endorphin        Group
[pg/ml] Several Seizures/
Control seizures/year /week
Mean 1.71 2.16 2.85
SD 0.44 1.38 1.07
SEM 0.18 0.44 0.40
N 6 10 7
Table VIII. Mean daily concentrations of b-endorphin in the
blood of patients with epilepsy in relation to duration of the
disease (groups less than and more than 10 years) and in the
control group
Tabela VIII. Średnie dobowe stężenie b-endorfiny we krwi
chorych na padaczkę w grupach wydzielonych w zależności
od czasu trwania choroby (mniej niż 10 lat lub ponad 10 lat)
i w grupie kontrolnej
b-endorphin        Group
[pg/ml] Duration less Duration more
Control than 10 years than 10 years
Mean 1.71 1.43 3.25
SD 0.44 0.39 1.04
SEM 0.18 0.15 0.30
N 6 7 10
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Table IX. Mean daily concentrations of leu-enkephalin in the
blood of patients with epilepsy in relation to frequency of
seizure occurrence (groups with seizure occurrence — several
per week and several per year) and in the control group
Tabela IX. Średnie dobowe stężenie leu-enkefaliny we krwi
chorych na padaczkę w grupach wydzielonych w zależności
od częstości napadów (kilka napadów na tydzień lub kilka
napadów na rok) i w grupie kontrolnej
Leu-enkephalin            Group
[pg/ml] Several Seizures/
Control seizures/year /week
Mean 1.34 1.24 1.09
SD 0.70 0.59 0.59
SEM 0.29 0.19 0.22
N 6 10 7
Table X. Mean daily concentrations of leu-enkephalin in the
blood of patients with epilepsy in relation to duration of the
disease (groups less than and more than 10 years) and in the
control group
Tabela X. Średnie dobowe stężenie leu-enkefaliny we krwi
chorych na padaczkę w grupach wydzielonych w zależności
od czasu trwania choroby (mniej niż 10 lat lub ponad 10 lat)
i w grupie kontrolnej
Leu-enkephalin            Group
[pg/ml] Duration less Duration more
Control than 10 years than 10 years
Mean 1.34 1.83 1.15
SD 0.70 0.57 0.50
SEM 0.29 0.21 0.14
N 6 7 10
of synthesis and secretion of endogenous opioid (leu-
enkephalin). Taking into consideration the fact that
hypophysectomy, not adrenalectomy, increases convul-
sion duration and abolishes progressive reductions in
convulsion severity, it seems that this endogenous opio-
id produced in the central nervous system might be
involved in the postictal refractory mechanism [34]. The
changes of opioid peptide reactivity in seizure activity
have been studied mainly in animals. It has been pro-
ven that b-endorphin shows anticonvulsive action if it
is liberated in small amounts. In conditions of mainta-
ined seizural activity when it is liberated in larger amo-
unts, it can participate in the development of status
epilepticus [35]. The observed increase of leu-enkepha-
lin content (but not b-endorphin and met-enkephalin)
in cerebrospinal fluid was not caused by taking antie-
pileptic drugs or by structural pathological changes of
the brain that might be found on CT scanning, but was
a manifestation of neurohormonal disorders of the bra-
in that resulted in epilepsy [1]. In another study, an in-
crease in leu-enkephalin, and to a smaller degree in met-
enkephalin-like immunoreactivity in the hippocampi
of adults with generalized epilepsy, was noted. The hip-
pocampi of six cadavers with a history of long-standing
grand mal seizures were submitted for analysis [5]. It
was shown that kappa-opioids in the hippocampus co-
unteract initiation and maintenance of status epilepti-
cus [2, 12], while delta-opioids promote initiation but
not maintenance of seizure activity [12]. It was also
shown that temporal lobe epilepsy is associated with
alterations in mu-opioid and nociceptin receptor bin-
ding and signal transduction mechanisms downstream
of these receptors [36]. The study of Zhang and Ko [37]
provides supporting evidence of seizure activity invo-
lved in the up-regulation of brain-derived neurotrophic
factor mRNA expression by activation of central mu-
opioid receptors. The anterior cingulate cortex, which
plays a role in pain, emotions, and behaviour, can ge-
nerate epileptic seizures. This structure presents a high
density of opioid receptors. Mu-opioid receptors appe-
ar to modulate both excitatory and inhibitory mechani-
sms, thus influencing epileptiform synchronization in
this brain region [38]. Transcriptionally less active pro-
dynorphin promoter alleles are associated with tempo-
ral lobe epilepsy, which might modify the risk of deve-
lopment of this epilepsy in subjects with a familial pre-
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disposition [7]. An increase in the met-enkephalin le-
vels in the striatum, cortex, pons, and medulla (but not
in the hippocampi) in the genetically epileptic (tg/tg)
mouse model of generalized epilepsy was noted [39].
Studies performed in rats showed an increase in enke-
phalin gene expression due to increased neuronal acti-
vity in the form of recurrent seizures [40], yet proenke-
phalin mRNA expression was increased after seizures
in specific brain regions [41, 42]. Met-enkephalin mRNA
was significantly increased in the hippocampus in rats
after seizures. Phenobarbital abolished the seizures and
the changes in neuropeptide expression [43]. Valproic
acid induced rapid changes in met-enkephalin levels
in the brains of rats with experimentally-caused epilep-
sy. This effect was also region specific. An increase in
this peptide was observed in the striatum, a decrease in
the midbrain, and no changes in the amygdala. These
results suggest that striatal met-enkephalin may parti-
cipate in the mechanism of the valproic acid-induced
anticonvulsant effect [44]. It seems that the pharmaco-
therapy used additionally in epilepsy, by its influence
on the endogenous opioid system, protects against li-
berating seizures and alleviates its clinical course [6].
Conclusions
1. Pituitary-adrenal axis hyperactivity is observed in
patients with clinically active epilepsy independen-
tly of the frequency of seizures and duration of the
disease.
2. Changes in endogenous opioid system activity are
related to the clinical activity of epilepsy — b-en-
dorphin plasma concentrations are connected with
frequency of seizures and duration of the disease,
and leu-enkephalin concentrations with duration of
the disease.
3. Endogenous opioid peptides might take part in the
neurochemical mechanism of human epilepsy.
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